AqT® Biotin-BSA-Deruxtecan

Product Description

AqT® Biotin-BSA-Deruxtecan is a novel dual-labeled BSA conjugate developed with CellMosaic's proprietary AqueaTether® (AqT®) linker technology, delivering enhanced assay performance. 

Drug–BSA conjugates are widely used in immunoassays, including bead-based assays, ELISA, and biosensor platforms such as SPR and BLI. In these applications, BSA serves as a carrier protein that facilitates the presentation of small-molecule drugs on assay surfaces. However, conventional drug–BSA conjugates typically rely on passive adsorption to plastic, glass, or bead surfaces, which can result in random orientation, variable surface density, and reduced assay reproducibility. By incorporating biotin into the drug–BSA conjugate, these limitations can be overcome through specific and controlled immobilization on streptavidin-coated surfaces. In this format, biotin acts as a molecular anchor, enabling robust, reproducible attachment of the drug–BSA conjugate while preserving accessibility of the drug moieties for target binding.

Furthermore, this conjugate can function as a modular drug delivery platform in which the targeting component can be swapped without resynthesizing the drug conjugate. This enables selective targeting and killing of cells that bind biotin-containing constructs. The system can also be used to evaluate albumin-mediated tumor accumulation, payload release kinetics, and the biodistribution of protein–drug conjugates.

However, developing dual-labeled drug–BSA conjugates is challenging because many drugs, including Deruxtecan (Mc-GGFG-DXd) are highly hydrophobic. Conjugation of multiple hydrophobic molecules to BSA often reduces aqueous solubility and promotes aggregation. Biotin also possesses hydrophobic character, which can further exacerbate these issues. As a result, dual-labeled drug–biotin–BSA conjugates are rarely available as commercial products.

CellMosaic’s proprietary AqT® super-hydrophilic linker technology addresses these challenges by enhancing aqueous solubility and minimizing aggregation. This Biotinylated BSA–Deruxtecan conjugate incorporates AqT® linkers to improve conjugate stability, reduce nonspecific interactions, and maintain excellent assay performance. The conjugate is engineered with an optimized drug-to-protein ratio (DPR) of approximately 3–5 Deruxtecan molecules per BSA and a biotin loading of approximately 2–4 biotin molecules per BSA, enabling efficient immobilization on streptavidin-coated surfaces. The hydrophilic AqT® linker helps minimize aggregation, reduce background signal, and improve assay robustness and reproducibility.

This product is sold as 1 tube each of 100µg (CM86171-500UG) and 500 µg (CM86171-500UG). For bulk quantities and custom packaging requirements, please contact us for pricing and availability.

For a detailed description of the AqT® technologies, please see our technology section.

Key Features 

• Lyophilized powder; ready for use after reconstitution with water. No additional buffer is required.
• Dual-functional conjugate containing an average of 2–4 Biotin molecules per BSA, enabling convenient immobilization on streptavidin-coated surfaces and compatibility with streptavidin-based detection systems. Optimal Deruxtecan Loading with an average of 3–5 Deruxtecan molecules per BSA.
• Deruxtecan incorporation levels accurately determined by UV/HPLC and MS analysis; biotin incorporation levels determined by biotin assay.
• Advanced AqT® linker technology: Utilizes CellMosaic’s proprietary, super-hydrophilic, water-soluble, charge-neutral AqT® linker to enhance aqueous solubility and minimize aggregation.

General Applications of Dual-Labeled AqT® Biotin-BSA-Deruxtecan Conjugate

ELISA, IHC, and ICC Assay Development: Detect and characterize anti-drug antibodies, drug-binding proteins, drug-binding receptors, and drug-specific monoclonal antibodies using streptavidin-coated surfaces.
Flow Cytometry Assays: Analyze anti-drug antibodies, drug-binding proteins, and drug-binding receptors using streptavidin-conjugated fluorophores.
Immunoprecipitation and Pull-Down Studies: Capture and enrich anti-drug antibodies, drug-binding proteins, and drug-binding receptors using streptavidin-coated beads.
SPR and BLI Binding Studies: Immobilize the conjugate on streptavidin-coated sensor surfaces for binding and kinetic studies.
Magnetic Bead–Based Assays: Capture, enrich, and isolate drug-binding proteins and antibodies using streptavidin-coated magnetic beads.
Microarrays and Multiplex Assays: Immobilize the conjugate on streptavidin-coated surfaces for high-throughput screening and multiplexed assay formats.
Streptavidin-Based Targeting Platform: A modular drug delivery system where the targeting component can be swapped without resynthesizing the drug conjugate. Screening different targeting ligands, preclinical targeting studies, cell-specific cytotoxicity assays.
Cell Ablation Reagent: The conjugate could be used to selectively kill cells that bind biotin-containing constructs. Examples: Engineered cells expressing avidin/streptavidin, cells decorated with streptavidin antibodies.
Pharmacokinetic and Albumin Delivery Research: Albumin-mediated tumor accumulation, payload release kinetics, biodistribution of protein-drug conjugates.

Specifications

• Physical Appearance: white to off-white preservative-free lyophilized powder in a 2.0 mL centrifuge tube.
• Storage Temp: –20°C or below.
• Purity: ≥99% of conjugates by HPLC.
• Amount of Biotin Loaded per BSA Molecule: 2–4 (refer COA of each lot for actual value).
• Amount of Deruxtecan Loaded per BSA Molecule: 3–5 (refer COA of each lot for actual value).

Characterization of AqT® Biotin-BSA-Deruxtecan Product by HPLC

Lot Number: S662.S11.0430F (Deruxtecan Loading: 4.5 by MALDI-TOF MS; Biotin Loading: 2.9 by Biotin Assay)

Figure 1. Overlay Reversed-phase HPLC spectrum of BSA (before labeling, green trace), BSA-Deruxtecan (after Deruxtecan labeling, red trace), and AqT® Biotin-BSA-Deruxtecan (after AqT® biotinylation, blue trace).

The hydrophilic AqT® linker largely preserves the retention time of the dual-labeled BSA conjugate, keeping it close to that of the BSA–Deruxtecan conjugate while exhibiting minimal peak broadening, indicative of improved conjugate homogeneity.

In contrast, BSA conjugated with 4.5 Deruxtecan molecules (the starting material for AqT® biotinylation) via the GGFG peptide linker exhibited a substantially longer retention time (ΔRt ≈ 0.3 min) and significant peak broadening (T½ ≈ 0.4 min).

Note: For biopolymers labeled with very hydrophobic small molecules, reversed phase HPLC can also be used to assess the extent of the labeling. 

Figure 2. Overlay SEC HPLC spectrum of BSA (before labeling, green trace), BSA-Deruxtecan (after Deruxtecan labeling, red trace), and AqT® Biotin-BSA-Deruxtecan (after AqT® biotinylation, blue trace).

AqT® biotinylation of BSA–Deruxtecan to an average DOL of 2.9 produces no detectable changes in apparent molecular weight or hydrodynamic volume. Native BSA contains approximately 8.6% aggregates, while Deruxtecan conjugation and subsequent AqT® biotinylation increase aggregate levels by 9.3% and 9.9%, respectively, resulting in a total aggregate content of 27.8%. Despite this increase, the conjugate remains well within an acceptable range for assay applications, with no precipitation observed.

These data highlight the ability of the AqT® linker technology to support dual protein labeling while preserving favorable biophysical properties.

Note: SEC separates the conjugates by apparent MW or size in aqueous solution. In general, higher-MW species elute earlier. SEC is also a useful tool for assessing the level of aggregation in a biopolymer. By comparing the SEC profiles of an unlabeled protein and labeled protein, you can estimate the extent of aggregation in the labeled protein. 

Frequently Asked Questions:

If you can’t find the answer you’re looking for or need information on general topics, please visit the main Frequently Asked Questions (FAQs) section.